Basic Clomipramine Information

• INN (International Nonproprietary Name): Clomipramine
• Brand Names Available In United Kingdom: Anafranil and generic equivalents; an oral solution is noted as existing in some markets (e.g. UK).
• ATC Code: N06AA04
• Forms & Dosages: Oral tablets 10 mg, 25 mg, 50 mg, 75 mg, 100 mg; prolonged‑release 75 mg tablets; capsules 25 mg and 50 mg; oral solution (exists in some markets, e.g. UK).
• Manufacturers In United Kingdom: not specified
• Registration Status In United Kingdom: not specified
• OTC / Rx Classification: Prescription‑only (Rx)

Key Findings From Recent Trials

Major 2022–2025 Studies

Which new evidence should clinicians notice about clomipramine for obsessive‑compulsive disorder and related uses?

Recent trials through mid‑2024 reinforce clomipramine’s robust efficacy for treatment‑resistant obsessive‑compulsive disorder.

Meta‑analytic signals show clinically meaningful symptom reduction compared with placebo in several pooled analyses.

Head‑to‑head work indicates faster response in some severe OCD cohorts compared with single SSRI trials, though differences vary by study population.

Smaller pragmatic trials since 2022 explored clomipramine in refractory depression and selected chronic pain syndromes.

Those trials were limited in size but suggest potential benefit for specific patients where other treatments failed.

Main Outcomes

What did the trials actually report about symptom change and remission?

Effect sizes in many clomipramine studies were greater than individual SSRI trials in treatment‑resistant OCD populations.

When combined with cognitive behavioural therapy, clomipramine produced comparable remission rates to augmentation strategies reported in specialist services.

Clinical audits emphasise improved control of intrusive thoughts and rituals in patients started on clomipramine tablets or Anafranil tablets after SSRI failure.

For depression and chronic pain the evidence is smaller but consistent with typical tricyclic antidepressant effects at usual doses.

Safety Observations

What safety signals should prescribers watch for in those trials and reports?

Trials and pharmacovigilance reports repeatedly flag anticholinergic and sedative adverse effects and cardiotoxicity risks.

Orthostatic hypotension and conduction changes were more common at higher doses and with polypharmacy.

Spontaneous reports continue to identify overdose cardiotoxicity and seizure risk, highlighting the need for structured titration and ECG monitoring.

Specialist guidance in the UK context therefore recommends baseline cardiac assessment and active management of anticholinergic burden.

Clinical Mechanism Of Action

Layman’s Explanation

How does clomipramine work in plain language?

Clomipramine is a tricyclic antidepressant that increases serotonin in the brain and, to a lesser extent, noradrenaline.

That increase helps reduce obsessive thoughts and low mood over weeks.

Side effects such as sleepiness or a dry mouth come from the drug’s actions at other receptors.

Scientific Breakdown

Receptor & Transporter Profile

What is the pharmacology behind those effects?

Clomipramine is a potent serotonin reuptake inhibitor with non‑selective inhibition of norepinephrine reuptake.

It antagonises muscarinic cholinergic receptors, histaminergic H1 receptors and alpha‑1 adrenergic receptors.

Those off‑target actions explain anticholinergic symptoms, sedation and orthostatic hypotension commonly seen with clomipramine hydrochloride.

Metabolism Implications

Which metabolic issues affect dosing and interactions?

Clomipramine is extensively metabolised by hepatic CYP enzymes, notably CYP1A2, CYP2C19, CYP2D6 and CYP3A4.

That makes it a substrate for multiple drug–drug interactions with CYP inhibitors and inducers.

Poor or ultra‑rapid metabolisers can have markedly different plasma concentrations, affecting efficacy and adverse effects.

Protein binding and active metabolites influence duration and tolerability, so dose adjustments in hepatic impairment and caution with potent CYP inhibitors are routine.

• Keywords naturally used here: clomipramine, clomipramine hydrochloride, Anafranil, clomipramine tablets, Anafranil tablets.

Scope Of Approved & Off‑Label Use

United Kingdom Approvals

Where does clomipramine sit in UK practice and licensing?

NICE and specialist commissioning in the UK generally reserve clomipramine for obsessive‑compulsive disorder when first‑line SSRIs and CBT are insufficient.

The drug is listed in European and international product monographs for OCD and depression, with off‑label use noted for chronic pain in some guidance.

In clinical practice clomipramine is therefore most often a second‑line or specialist‑initiated option for OCD.

Notable Off‑Label Trends

When do clinicians use clomipramine off label?

Off‑label utilisation has increased for refractory depression and certain neuropathic pain syndromes where other agents failed.

Some specialists use clomipramine for panic disorder or selected anxiety presentations under close supervision.

Paediatric use for OCD is established in some regions with specialist dosing and monitoring.

UK prescribers balance the higher efficacy in some OCD cohorts against tolerability and monitoring needs before recommending clomipramine.

Dosage Strategy

General Dosing

What is the safe way to start clomipramine?

Start low and escalate slowly to balance effect with side effects.

Typical adult initiation is 10–25 mg/day with gradual up‑titration as tolerated.

Maintenance doses commonly fall between 75–150 mg/day in divided doses.

Extremely resistant cases can require doses up to a maximum of 250 mg/day, per product information.

Condition‑Specific Dosing

How do targets differ by diagnosis?

For obsessive‑compulsive disorder a common maintenance target is 100–150 mg/day after titration from 25 mg/day.

Major depressive disorder often starts at 25 mg/day with maintenance typically 75–150 mg/day.

Panic disorder and chronic pain regimens frequently mirror the lower‑end tricyclic strategies, often 50–150 mg/day maintenance.

Children require specialist titration (start around 25 mg/day, adolescent maxima ≈200 mg/day).

Elderly patients start at 10–25 mg/day and increase very slowly because of anticholinergic and sedative sensitivity.

Hepatic or renal impairment warrants lower starting doses and careful titration with specialist pharmacokinetic advice where needed.

Safety Protocols

Contraindications

Who must not take clomipramine?

Absolute contraindications include known hypersensitivity to tricyclics, recent myocardial infarction and severe cardiac arrhythmias.

Concurrent or recent monoamine oxidase inhibitor therapy is an absolute contraindication; allow at least 14 days after MAOI discontinuation.

Relative contraindications that require monitoring include cardiovascular disease, epilepsy, urinary retention, glaucoma and significant hepatic or renal impairment.

Adverse Effects

Which side effects are common and which are serious?

Common adverse effects include drowsiness, dry mouth, constipation, blurred vision and urinary retention due to anticholinergic activity.

Weight gain, sexual dysfunction, tremor, sweating and orthostatic hypotension are also commonly reported.

Serious risks include cardiac conduction abnormalities such as QT prolongation, arrhythmias, seizures at high doses and overdose cardiotoxicity.

Baseline assessment should include ECG for cardiac risk, a review of concurrent medicines and consideration of liver function tests.

Interaction Mapping

Food Interactions

Are there any foods or drinks to avoid?

Avoid alcohol because of additive sedation and increased risk of falls or orthostatic hypotension.

Classical tyramine restrictions do not apply to clomipramine as they do with MAOIs.

Drug Combinations To Avoid

Which medicines are dangerous with clomipramine?

Concurrent MAOI use is an absolute contraindication.

Strong CYP inhibitors or inducers of CYP1A2, CYP2C19, CYP2D6 and CYP3A4 can raise or lower clomipramine plasma levels considerably.

Other serotonergic drugs increase the risk of serotonin syndrome when combined with clomipramine, so take care with SSRIs, SNRIs, triptans and some opioids.

QT‑prolonging drugs and other anticholinergics potentiate cardiac or anticholinergic harms.

Caution is needed with antipsychotics, antiarrhythmics and anticonvulsants because of effects on seizure threshold and conduction.

Practical steps include a full medication reconciliation, dose reduction with potent CYP inhibitors and ECG monitoring if QT‑prolonging combinations are unavoidable.

Patient Experience Analysis

Survey Data

What do patients report in routine practice?

Clinic audits and surveys often show substantial symptomatic relief in OCD and some depressive presentations after starting clomipramine.

Many patients describe rapid control of intrusive thoughts and rituals when clomipramine is added after SSRI failure.

Tolerability remains the chief reason for discontinuation, most commonly sedation, dry mouth, constipation, weight gain and sexual dysfunction.

Forum Trends

What do online patient communities say?

Patient forums echo the clinical picture: clear benefit for some, but a steep side‑effect trade‑off for others when switching from an SSRI to Anafranil.

Quality‑of‑life improvements occur when side effects are actively managed with dose timing and adjunctive measures.

Shared decision‑making, written information and specialist pharmacist counselling in the UK improve adherence and safety.

Distribution & Pricing Landscape

Where can patients get clomipramine and what are the price drivers?

Clomipramine is available as branded Anafranil and multiple generics in tablet strengths commonly from 10 mg to 100 mg.

Major suppliers include Novartis, Sun Pharma, Torrent and Sanofi, with regional brands such as Clonil in some markets.

In the UK it is prescription‑only and supplied through community and hospital pharmacies and under NHS prescribing when clinically indicated.

Generic options typically lower the cost compared with branded Anafranil and NHS formularies tend to favour generics for procurement.

Our online pharmacy lists clomipramine for patients and offers discreet delivery across the United Kingdom in 5‑14 days.

Alternative Options

Comparison Table

How does clomipramine compare with other antidepressants and OCD treatments?

SSRIs such as fluoxetine and sertraline are first‑line for OCD and depression in UK practice because of better tolerability.

Other TCAs like amitriptyline and nortriptyline have similar classes of adverse effects; amitriptyline is often preferred for pain because of sedative properties.

SNRIs such as venlafaxine and duloxetine are effective for depression, anxiety and neuropathic pain but have less evidence for OCD compared with clomipramine.

Pros And Cons

What are the trade‑offs when choosing clomipramine?

Pros: strong evidence of efficacy in refractory OCD and potent serotonergic blockade that can produce clinical remission when SSRIs fail.

Cons: higher anticholinergic burden, cardiac risk, complex drug interactions and additional monitoring compared with SSRIs.

Choice depends on symptom severity, comorbidity and the patient’s tolerance for side effects.

Regulatory Status

Agency Approvals & Scheduling

What do regulators say about clomipramine?

The FDA approves clomipramine for obsessive‑compulsive disorder, with off‑label notes for depression, panic and chronic pain.

The EMA and other national agencies include approvals for OCD, depression and some chronic pain indications.

Clomipramine is prescription‑only in regulated markets worldwide.

United Kingdom‑Specific Guidance

How is prescribing typically managed in the UK?

NICE places SSRIs and CBT as first‑line treatments for OCD, with clomipramine considered in secondary or specialist care when first‑line options are inadequate.

UK practice emphasises cardiac assessment, medication reconciliation and specialist monitoring when prescribing clomipramine.

Consolidated FAQ

Short Q&A For Clinicians & Patients

Q: What is the usual starting dose?

A: Start at 10–25 mg/day and titrate slowly; maintenance often 75–150 mg/day with a maximum around 250 mg/day.

Q: Is an ECG required?

A: A baseline ECG is recommended for patients with cardiac risk and should be repeated for high doses or when new interacting medicines are added.

Q: Can it be used in children?

A: Paediatric OCD use is established in some regions under specialist supervision, typically starting at 25 mg/day with cautious titration.

Q: What about pregnancy?

A: Use requires a specialist risk–benefit discussion and should not be stopped abruptly in pregnancy without clinical advice.

Q: What to do for missed doses?

A: Take the missed dose as soon as remembered unless it is near the next dose; do not double up.

Q: What are overdose signs?

A: Seek emergency care for cardiac arrhythmias, seizures, severe hypotension or loss of consciousness.

Visual Guide

Suggested Figures & Infographics

What visuals help clinicians and patients understand clomipramine safely?

Recommended materials include a dose‑titration chart showing initiation at 10–25 mg and target ranges per indication.

A mechanism diagram mapping SERT/NET inhibition and off‑target muscarinic/H1/alpha‑1 effects to common side effects is useful.

A monitoring checklist should list baseline ECG, review of CYP‑metabolised co‑meds, liver function tests and a follow‑up schedule.

A safety flowchart for suspected overdose (cardiac monitoring, seizure precautions, urgent transfer) reduces delays in emergency care.

Packaging images of Anafranil tablets and common generics help dispensing teams avoid errors.

Storage & Transport

How should clomipramine be stored and handled in pharmacy practice?

Store at 25°C with permitted excursions between 15–30°C and protect from light and moisture.

Transport in original packaging and do not use past the expiry date.

Community pharmacies and hospital services should keep secure labelled stock and temperature logs where bulk storage is required.

Advise patients to keep tablets in original blister packs, store in a dry place away from children and pets and avoid bathroom cabinets where humidity fluctuates.

Guidelines For Proper Use

Initiation & Monitoring Checklist

What practical steps ensure safe initiation?

Confirm the indication, perform baseline ECG if cardiac risk is present and do a medication reconciliation focusing on MAOIs and CYP interactions.

Record baseline weight and blood pressure and counsel about anticholinergic effects.

Start at 10–25 mg/day with weekly to fortnightly upward titration as tolerated and follow up at 2–4 weeks initially.

Repeat ECG for unexplained syncope, high doses or newly added QT‑prolonging drugs.

Tapering & Discontinuation

How should clomipramine be stopped to avoid withdrawal?

Taper gradually over weeks to months to reduce discontinuation symptoms such as nausea, headache and sleep disturbance.

Abrupt cessation is not advised.

Special populations such as the elderly and children require slower titration and specialist oversight for stopping and starting.

Provide a written safety plan and emergency instructions about overdose to every patient.

Delivery Across United Kingdom